Home › Non-Small Cell Lung Cancer › Texas › Round Rock
Non-Small Cell Lung Cancer clinical trials in Round Rock, TX
4 studies for Non-Small Cell Lung Cancer are looking for participants at sites in and around Round Rock (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
RecruitingPhase 1
- Research Site, Round Rock
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
RecruitingPhase 3
- Baylor Scott & White Health - Round Rock, Round Rock
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
RecruitingPhase 3
- Research Site, Round Rock
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
RecruitingPhase 3
- Research Site, Round Rock
Non-Small Cell Lung Cancer trials in other cities
- Houston, TX145 studies
- New York City, NY120 studies
- Arlington, VA104 studies
- Nashville, TN97 studies
- Boston, MA90 studies
- Los Angeles, CA87 studies
- St. Louis, MO73 studies
- Chicago, IL61 studies
- Baltimore, MD60 studies
- San Antonio, TX59 studies
- Columbus, OH56 studies
- Washington, DC55 studies
Other studies in Round Rock
- Parkinson's Disease9 studies
- Ulcerative Colitis8 studies
- Crohn's Disease7 studies
- Steatotic Liver Disease7 studies
- Inflammatory Bowel Disease5 studies
- Alzheimer's Disease4 studies
- Obesity4 studies
- Type 2 Diabetes4 studies
- Mild Cognitive Impairment3 studies
- Colorectal Cancer3 studies
- Liver Diseases3 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.